- Company recently announced significant findings of cardiovascular performance improvements with TurboCBD
- Lexaria plans additional human clinical trials of CBD
- Company is now moving forward with clinical studies on oral forms of nicotine delivery following a large investment agreement
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is a food bioscience company that developed and commercialized cost-effective drug delivery platform DehydraTECH. This technology enhances the performance of beneficial compounds in ingestible products. Currently, Lexaria has patents pending worldwide for use of the technology in a range of bioactive molecules, including cannabinoids, nicotine, NSAID pain relievers and more. Leveraging this platform, the taste, smell, speed of action, bioabsorption and bioavailability of oral ingestion is improved without the harmful practices of lighting up or the unhealthy additions of sugars and sweeteners. The company licenses DehydraTECH to other companies around the world to enhance already established, quality product lines.
TurboCBD is Lexaria’s proprietary DehydraTECH-powered, CBD-fortified hemp-oil capsule. The capsules are formulated with full-spectrum hemp oil, ginseng and ginkgo for enhanced focus and memory. They are marketed as a mental and physical boost aimed at helping to remove brain fog, fatigue and stress. TurboCBD is molecularly engineered for quick and high absorption rates into the circulatory system.
In a recent press release (http://ibn.fm/OwOtT), Lexaria announced that the results from a healthy-human clinical trial provided evidence that a single 90mg dose of TurboCBD resulted in lower blood pressure, higher blood flow to the brain, faster delivery onset of CBD into the bloodstream and larger quantities of CBD within the blood as compared to an equal dose of generic CBD. Due to the positive results of this study, the company plans to conduct additional human clinical trials over the course of the next year using DehydraTECH in CBD.
A comprehensive series of clinical studies will also continue on oral forms of nicotine delivery. Lexaria Nicotine LLC, a wholly owned subsidiary, has entered into an investment agreement that will provide an initial $1 million, with additional funding of up to $12 million, toward the research and development of nicotine consumer products enhanced by DehydraTECH.
DehydraTECH is an enabling drug-delivery platform with relevance across multiple industries. The company utilizes subsidiaries that reach across industry lines, making it accessible to the medical and recreational cannabis industries and pharmaceutical sectors. The company has formed a partnership with one of the world’s largest tobacco companies (http://ibn.fm/v91xQ). Currently, Lexaria owns 10 patents with over 50 patents pending worldwide for this revolutionary technology. Lexaria is ahead of the game, doing business on its terms and attracting the attention of Fortune 500-type corporations.
For more information, visit the company’s website at www.LexariaBioscience.com
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
